In the September 27th, 2022 Supplement

New Federal R&D Funding Opportunities

Department of Health and Human Services

Advancing Methods for Safe, Noninvasive, Real Time Assessment of Placenta Development and Function Across Pregnancy

The Eunice Kennedy Shriver National Institute of Child Health and Human Development is inviting grant applications that seek to advance or clinically validate emerging novel approaches for the development of safe, real-time, non-invasive (or minimally invasive) methods to assess the development and function of the human placenta across pregnancy. This opportunity is for the advancement of novel methods for assessing the placenta's real time *in vivo* status with the ultimate goal of human use across pregnancy. Special consideration will be given to applications that develop methods that are applicable throughout pregnancy, preferably starting in early gestation during the period of trophoblast invasion and remodeling of the uterine spiral arteries, and which facilitate assignment of relative risk for pregancy complications. Two funding opportunities are offered, varying by the proposed project's stage in the R&D process.

- **Research Project Grant:** For this opportunity (PAR-22-237) applications are due February 5th, 2023.
- **Exploratory Development/Research Grant:** For this opportunity (PAR-22-236) applications are due February 16th, 2023.

Awards:
Multiple awards are anticipated.

Eligibility:
Unrestricted

Deadline:
02/16/2023

AwardsID(s):
PAR-22-236, PAR-22-237

Links:
https://grants.nih.gov/grants/guide/pa-files/PAR-22-236.html, https://grants.nih.gov/grants/guide/pa-files/PAR-22-237.html

AHRQ Mentored Research Scientist Career Development Award

The Agency for Healthcare Research and Quality (AHRQ) is soliciting applications to the Mentored Research Scientist Development Award (K01) to provide salary and research support for a sustained period of "protected time" (3-5 years) for intensive research career development, under the guidance of an experienced mentor. The expectation is that, through this sustained period of research career development and training, candidates will launch independent research careers and become competitive for new research project grant funding. Applications must be responsive to AHRQ's mission, which is to produce evidence to make health care safer, higher quality, more accessible, equitable and affordable, and to work with the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used.

Awards:
Multiple Awards are anticipated

Eligibility:
Unrestricted Domestically

Deadline:
01/15/2022

AwardsID(s):
PA-22-255

Links:
https://grants.nih.gov/grants/guide/pa-files/PA-22-255.html

BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain

Multiple NIH Institutes are soliciting aplications to the BRAIN Initiative to understand the circuits and patterns of neural activity that give rise to mental experience and behavior. Proposed projects could develop tools to integrate existing theories or formulate new theories;

conceptual frameworks to organize or fuse data to infer general principles of brain function; multiscale/multiphysics models to generate new testable hypotheses to design/drive future experiments; new analytical methods to substantiate falsifiable hypotheses about brain function.

Awards:
15 awards from a pool of $6 million

Eligibility:
Unrestricted

Deadline:
09/23/2022

AwardsID(s):
RFA-DA-23-039

Links:
https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-039.html

Clinical Coordinating Center for the Network of Excellence in Neuroscience Clinical Trials

The National Institute of Neurological Disorders and Stroke is soliciting applications for participation in the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). The purpose of the network is to efficiently conduct multiple, scientifically sound, possibly biomarker-informed exploratory clinical trials evaluating the most promising therapies, and to facilitate collaborations between academia, industry, non-profit foundations, government organizations, and other possible stakeholders. Three separate soliciations are offered for the various components of the network:

- Opportunity RFA-NS-22-031 (see link below) is for proposals for multiple renewals and new **NeuroNEXT sites**. NINDS anticipates making up to 25 awards from a total pool of $6.875 million.
- Proposals for the **Clinical Coordinating Center**, to serve as hub among NeuroNEXT sites, should respond to RFA-NS-22-029 (see link below). NINDS anticipates making a single $1.75 million award for this opportunity.
- Proposals for the **Data Coordinating Center** aggregating information collected thrugh

the NeuroNEXT sites should use RFA-NS-22-030 (see link below). NINDS anticipates a single $1.3 Million award.

Eligibility:
Unrestricted Domestically

Deadline:
11/21/2022

AwardsID(s):
RFA-NS-22-029, RFA-NS-22-030, RFA-NS-22-031

Links:
https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-029.html, https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-030.html, https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-031.html

Consortium for Design of TB Drug Regimens

The National Institute of Allergy and Infectious Diseases is soliciting applications to establish a consortium of tuberculosis preclinical and clinical experts to systematically refine preclinical models by analyses of relevant pre-clinical and clinical data, and to provide results from optimized models to identify the most efficacious combination regimens for future clinical testing through model-informed research. By generating adequate and comparable preclinical data on regimen efficacy, pharmacometrics, toxicities, drug-drug interactions, and other factors essential for human clinical trials, the consortium will increase efficiency, accelerate development of new combinations, and identify the most promising regimens for future clinical testing to effect shorter, relapse-free cures of pulmonary TB in adults, children, and persons being treated for HIV.

Awards:
one award of $7.2 million

Eligibility:
Unrestricted Domestically

Deadline:
02/07/2022

AwardsID(s):
RFA-AI-22-059

Links:
https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-059.html

Diversity Centers for Genome Research

Multiple NIH Institutes are soliciting applications to establish Genomic Research Centers at Minority Serving Institutions. Each project should address one or more critical issues in genomics, including: genomic technology and methods development; genome structure; genome function; genomics of disease; use and impact of genomic information in clinical care; genomic data science and computational genomics; ethical, legal, and social implications of genomic research; and/or genomics and health equity. Two different grant mechanisms will be deployed, dependent on project design. Respondents must apply to the appropriate, separate opportunity for consideration:

- **Specialized Center- Cooperative Agreements:** Awards made under this opportunity (RFA-HG-22-026) will be cooperative agreements. A Consortium will be organized with the principal investigators, key personnel of the Centers funded under this opportunity and the companion opportunity. 2-3 awards from a pool of $5 million will be provided.
- **Exploratory Developmental Phased Award:** This opportunity (RFA-HG-22-027) will utilize a UG3/UH3 cooperative agreement mechanism for a two-stage, one-application approach to the development of a full-scale Diversity Center for Genome Research. Phase I will provide up to $300,000 direct costs per year not to exceed three years, to plan for and demonstrate the ability to fulfill the goal of operationalizing a full-scale Diversity Center for Genome Research in Phase II. 3-5 awards from a pool of $1.5 million will be provided.

Eligibility:
Unrestricted Domestically

Deadline:
12/06/2022

AwardsID(s):

RFA-HG-22-026, RFA-HG-22-027

Links:
https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-22-026.html, https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-22-027.html

HEAL Data2Action – Innovation and Acceleration Projects, Phased Awards

Multiple NIH Institutes are soliciting applications to the HEAL Data2Action (HD2A) Program, a coordinated effort to promote the synthesis and real-world application of existing data to improve epidemiology and guide and monitor improvements in service delivery to prevent or treat opioid use disorder. Two funding opportunities have been released, varying by whether or not proposals include clinical trials.

- **Clinical Trial Optional:** In this opportunity (RFA-DA-23-057) research projects will focus on one of two priorities: **Priority 1 –** develop data or methods that improves the timeliness, quality, accessibility or usefulness of existing data ecosystems (*Acceleration Projects*) or **Priority 2 -** leveraging single system or cross-sector partnerships to use data to identify and fill service delivery gaps with evidence-based strategies and monitor improvements (*Innovation Projects*). Applicants should specify which Priority they are responding to in their applications.
- **Clinical Trial not Allowed:** In this opportunity (RFA-DA-23-058), research projects will focus on developing data or methods that improves timeliness, quality, accessibility, or usefulness of existing data ecosystems to allow for faster and improved responses and allocation of resources to address the overdose crisis.

Awards:
6-8 awards from a pool of $5 million

Eligibility:
Unrestricted Domestically

Deadline:
11/22/2022

AwardsID(s):
RFA-DA-23-057, RFA-DA-23-058

Links:
https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-057.html, http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-058.html

Large Scale Integrated Mapping and Molecular Profiling of Cell Ensembles and/or Cell-Types Mediating Opioid Action in the Rodent Brain

The National Institute on Drug Abuse is soliciting applications to support complementary research programs that adopt innovative scalable technologies to inventory, register and profile cellular ensembles and/or cell-types that produce and/or respond to opioids in the rodent brain, or that are engaged during different stages of opioid use (acute, chronic, withdrawal, abstinence, relapse). The overarching goal of this opportunity is to deliver multimodal reference datasets that will constitute useful resources to the research community and will provide a foundational biological framework to advance the understanding and treatment of opioid-associated states.

Awards:
1-3 awards from a pool of $2 million

Eligibility:
Unrestricted

Deadline:
02/02/2023

AwardsID(s):
RFA-DA-23-035

Links:
https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-035.html

NIAID Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity

The National Institute of Allergy and Infectious Diseases is soliciting applications for a research project grant to support either: a) a New Investigator, an individual who has not previously competed successfully for substantial, independent funding from NIH; or b) are an 'At-Risk'

investigator, an individual who had prior support as a PD/PI on a substantial independent research award. Research areas include microbiology and infectious diseases, AIDS, and AIDS - related research, immunology, allergy, transplantation, and emerging and re-emerging infectious diseases.

Awards:
Multiple awards are anticipated.

Eligibility:
Unrestricted Domestically

Deadline:
12/07/2022

AwardsID(s):
PAR-22-241

Links:
https://grants.nih.gov/grants/guide/pa-files/PAR-22-241.html

Schizophrenia and related disorders during mid- to late-life

The National Institute of Mental Health is soliciting applications that will advance translational research to better understand the emergence, trajectory, and outcomes of schizophrenia and related psychotic disorders in mid- to late-life, and to identify targets for future development of prevention and treatment interventions. Two solicitations hae been released, each designed to accommodate projects at different stages of the process. Applicants with preliminary data who seek longer-term funding should apply using RFA-MH-22-270, designed for **Research Projects** (see link below). Investigators proposing high risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism, **Exploratory Development Grants**, and should use opportunity RFA-MH-22-271.

Awards:
5-7 awards from a pool of $3 million across both funding mechanisms

Eligibility:
Unrestricted

Deadline:

02/22/2023

AwardsID(s):
RFA-MH-22-270, RFA-MH-22-271

Links:
https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-270.html, https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-271.html

New SBIR/STTR Funding Opportunities

Botulinum Toxin Potency Assay using Tissue Chips

Multiple NIH Institutes are soliciting SBIR and STTR applications to establish the Botulinum Toxin Potency Assay using Tissue Chips (BoT PATCh) as a Drug Development Tool. A main objective for this funding opportunity would be to position BoT PATCh as an alternative test method that can be utilized as a stand-alone replacement for mouse lethality bioassay. Separate solicitations have been released for the two programs, both support applications for the qualification of neuromuscular junction tissue chips as an alternative approaches method to replace the current LD50 (lethal dose) assay mouse lethality bioassay as a potency assay for botulinum toxin. For STTR, use RFA-TR-22-031. For SBIR use RFA-TR-22-032.

Awards:
Three phase I proposals are expected from each program.

Eligibility:
Unrestricted Domestically

Deadline:
11/21/2022

AwardsID(s):
RFA-TR-22-031, RFA-TR-22-032

Links:
https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-22-031.html, https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-22-032.html

New Foundation R&D Funding Opportunities

American Association of Critical-Care Nurses

Nursing Impact Research

The Association invites applications to support work to address gaps in high-acuity and critical care areas of clinical research. Three grants will be awarded to support projects that support inquiry and systematic research that generates new knowledge. These grants also will facilitate research to support other AACN priorities, such as describing the impact of family presence, influencing nurse certification, and implementing standards for healthy work environments. Grants will ensure a pipeline for research that is vital to AACN's research translation resources, such as protocols and practice alerts.

Awards:
3 awards of $50,000

Eligibility:
Must hold an earned master's degree or have completed candidacy requirements in a BSN-to-PhD or DNP program.

Deadline:
10/28/2022

Links:
https://www.aacn.org/nursing-excellence/grants/aacn-impact-research-grant

Orthopaedic Research and Education Foundation

Orthopaedic Resident Research Grants

The Foundation seeks applications to support orthopadedic surgery residents interested in research. It covers research expenses but not salary or travel. Work should be achievable by the resident as a free-standing project even when it is a part of a larger work. Letters of intent are required and must be submitted by October 17 for consideration in the winter funding cycle.

Awards:
Up to four grants of $5,000

Eligibility:
Orthopaedic surgery residents in an ACGME-Accredited orthopaedic program in the United States.

Deadline:
10/17/2022

Links:
https://www.oref.org/grants-and-awards/grant-programs/grant-program-information#res1

Pfizer

Transthyretin Amyloid Cardiomyopathy awareness and understanding

Pfizer invites applications for its Local Level Educational Grants Program to Increase Awareness & Understanding of Transthyretin Amyloid Cardiomyopathy. Projects that will be considered for Pfizer support will improve the care of patients by addressing one of with topics:

1. educating healthcare professionals to increase awareness and enable appropriate and early patient identification by closing knowledge gaps in disease epidemiology, pathophysiology, diagnosis, and emerging treatment paradigms;
2. increasing awareness of at-risk and undiagnosed populations with TTR amyloidosis with a focus on improving strategies that facilitate the appropriate diagnosis of patients early in the disease course before overt cardiomyopathy has ensued [e.g., populations with electrical disturbances, valvular disease, orthopedic manifestations, and cardio-oncology diseases;
3. identifying significant barriers that contribute to geographic and racial healthcare disparities disproportionately impacting the hereditary ATTR-CM subtype patient population and addressing these challenges to increase earlier diagnosis and treatment;
4. supporting the dissemination of information related to systematic strategies that facilitate earlier appropriate identification and diagnosis and reduce the burdens for patients and providers along the diagnostic pathway;

5. increasing awareness and understanding of the role of imaging in the early identification of patients with ATTR-CM and the role of bone radiotracer scintigraphy as a non-invasive alternative for the appropriate diagnosis of TTR cardiac amyloidosis in select patients;

6. increasing awareness of the changing epidemiology of TTR amyloidosis with a focus on the prevalence of hereditary ATTR-CM and wild-type ATTR-CM subtypes as the science continues to evolve;

7. supporting the dissemination of information related to the pharmacologic and non-pharmacologic management of ATTRCM; and

8. addressing challenges to appropriate diagnoses and caring for patients during an era of increased telehealth utilization.

Awards:
Multiple awards ranging between $10,000 and $20,000

Eligibility:
U.S.-based medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other related entities.

Deadline:
10/28/2022

Links:
https://philanthropynewsdigest.org/rfps/rfp14247-pfizer-issues-rfp-for-projects-to-increase-awareness-and-understanding-of-transthyretin-amyloid-cardiomyopathy

Terms and Conditions for redistribution or republication of the SSTI Funding Supplement

Preparation of the *SSTI Funding Supplement* is possible only through the financial support of dues-paying SSTI member organizations. Use of the *SSTI Funding Supplement* is subject to the following terms and conditions:

- Only the primary member contact, or their SSTI-approved designee, may redistribute this newsletter and/or its content and under no circumstances may the *SSTI Funding Supplement* be placed on a website or database accessible to the general public.

- Any redistribution must be limited to the SSTI member organization's staff, faculty,

membership, partner organizations, and client companies.

- All redistributions must include fundingsupplement@ssti.org in the distribution list, give credit to SSTI (including a link to https://ssti.org), and include this Terms and Conditions statement.
- Those receiving a redistributed version of the *SSTI Funding Supplement* may not forward those emails to others or make them available to the public.
- With prior permission from SSTI, only the primary member contact, or their SSTI-approved designee, may post back issues of the *SSTI Funding Supplement* on internal and password-protected sites only.

If you have any questions about these terms, to request approval of a primary contact's designee, or to discuss an alternative licensing agreement, please contact Colin Edwards at fundingsupplement@ssti.org.